Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriasis Vulgaris Clear all
Not listed Phase 4 Interventional

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

NCT03307447
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Secukinumab
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 in the Treatment of Psoriasis Vulgaris

NCT01536938
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Calcipotriol, Betamethasone
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Recruiting Phase 4 Interventional

Psoriatic Immune Response to Tildrakizumab

NCT05390515
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Tildrakizumab Prefilled Syringe
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
Skin biopsies
Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

NCT03022617
View directory record Official record
Conditions
Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

NCT00817219
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene plus betamethasone dipropionate ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Fremont, California • San Diego, California • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

NCT00704262
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus hydrocortisone (LEO 80190)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

NCT01806597
View directory record Official record
Conditions
Moderate to Severe Palmoplantar Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

NCT04633616
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis, Acne
Interventions
Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 22, 2026, 4:47 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

Topical SGX302 for Mild-to-Moderate Psoriasis

NCT05442190
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Hypericin, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 4:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Research Study Participant Registry

NCT00710489
View directory record Official record
Conditions
Acne, Actinic Keratosis, Dysplastic Nevi, Eczema, Psoriasis, Skin Cancer, Rosacea, Leg Ulcers, Foot Ulcers, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

CT 327 in the Treatment of Psoriasis Vulgaris

NCT00995969
View directory record Official record
Conditions
Psoriasis
Interventions
placebo, CT 327
Drug
Lead sponsor
Creabilis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

NCT02317627
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
KD025
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Glendale, Arizona • Santa Ana, California • Lake Charles, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene/betamethasone gel and ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Blue Light Phototherapy

NCT04343586
View directory record Official record
Conditions
Grover's Disease, Psoriasis Vulgaris
Interventions
Blue light phototherapy
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

NCT03322137
View directory record Official record
Conditions
Pruritus, Psoriasis Vulgaris
Interventions
SNA-120, Vehicle
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

NCT02106195
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Belumosudil
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
39
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 22, 2026, 4:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep, Circadian Rhythm & Skin Health

NCT02457000
View directory record Official record
Conditions
Healthy, Psoriasis, Eczema, Acne
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Jul 22, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.

NCT00220025
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Phototherapy
Device
Lead sponsor
Mary Sullivan-Whalen
Other
Eligibility
14 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 22, 2026, 4:47 AM EDT